Solventum has delivered four consecutive quarterly earnings beats with an average surprise of 8.8%, demonstrating reliable profit execution in medical instruments, though weak price momentum and a poor free-cash-flow ratio relative to net income limit near-term entry appeal.
Thesis pillars
- Valuation Margin Of Safety→Stable
- Consistent Earnings Beat Streak→Stable
- Return On Equity Peer Advantage→Stable
- +1 more pillar — see the Why tab for full reasoning
Solventum Corporation (SOLV) Stock Analysis
Range Bound setup
Healthcare · Medical Instruments & Supplies
Sell if holding. Analyst target reached at $78.27 — A.R:R is negative (-1.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: MedSurg segment (57.9%).
Solventum, spun off from 3M in April 2024, develops and commercializes healthcare solutions through MedSurg (57.9% of 2025 total sales), Dental Solutions (16.2%), and Health Information Systems (16.3%), with products sold in over 90 countries. Revenue comes from medical device,... Read more
Sell if holding. Analyst target reached at $78.27 — A.R:R is negative (-1.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: MedSurg segment (57.9%). Chart setup: RSI 47 mid-range, Bollinger mid-band. Score 4.8/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 34d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
About Solventum Corporation
About Solventum Corporation
Solventum generated 2025 revenue across three operating segments: MedSurg (57.9% of total sales), covering wound therapy, I.V. site management, sterilization assurance, and surgical supplies; Dental Solutions (16.2%), spanning orthodontic brackets, aligners, and restorative products; and Health Information Systems (16.3%), providing clinical documentation software, coding automation, and speech recognition tools. The company employs approximately 20,000 people globally, including about 10,000 in the United States and 2,000 in Germany, and sells in over 90 countries.
Solventum sells through a multi-model commercial approach — direct-to-customer, distribution, key account management, inside sales, and e-commerce — supported by clinical specialists, medical liaisons, and application engineers. Products are purchased principally by hospitals, physicians, and other healthcare providers that bill Medicare, Medicaid, and private insurance payers. MedSurg competitors include Smith & Nephew, Mölnlycke, Coloplast, and Becton Dickinson; dental competitors include Dentsply Sirona, Envista, Straumann, and Align Technology; Health Information Systems competes with Optum, Microsoft (Nuance), Epic, and Oracle (Cerner). In 2025, the company acquired Acera Surgical and divested its Purification and Filtration business to Thermo Fisher Scientific. Solventum carries approximately $5 billion in outstanding indebtedness as of December 31, 2025, incurred during the April 2024 spin-off from 3M, and continues to operate some distribution and manufacturing under transition agreements with 3M.
Show full overview
Solventum's most structural post-spin risk is continued operational reliance on 3M under more than a dozen named agreements. The 10-K states the company is relying on 3M to satisfy its obligations under the 3M Agreements not only for a successful transition but also for the success of its long-term operations, and the Tax Matters Agreement restricts equity issuances, share repurchases, and certain acquisitions for two years following the distribution. Separately, on March 20, 2026, Chief Accounting Officer Mary Wilcox notified Solventum of her intent to retire following appointment of a successor — a finance leadership transition that adds to the ongoing 3M separation complexity.
See also: Healthcare · Medical Instruments & Supplies
From Solventum Corporation's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-07-06Recent Developments — Solventum Corporation
Latest news
- NEWS SOLV vs. HQY: Which Stock Is the Better Value Option? - Yahoo Finance — Yahoo Finance neutral
- NEWS Solventum (SOLV) Projected to Post Earnings on Tuesday - MarketBeat — MarketBeat neutral
- NEWS Solventum (SOLV) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance — Yahoo Finance positive
- NEWS Solventum (NYSE:SOLV) Exceeds Q1 CY2026 Expectations - StockStory — StockStory positive
- NEWS Solventum gains after activist Trian sends letter urging changes (update) (SOLV:NYSE) - Seeking Alpha — Seeking Alpha positive
Generated 2026-07-06T04:40:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductMedSurg segment58%10-K Item 1: 'MedSurg (57.9% of 2025 total sales)'
- MEDIUMcounterparty3M dependency10-K Item 1A: 'Solventum is relying on 3M to satisfy its obligations under the 3M Agreements not only for a successful transition but also for the success of its long-term operations.'
Material Events(8-K, last 90d)
- 2026-05-27Item 5.02LOWTalent Committee adopted new Executive Severance Plan effective June 1, 2026, replacing prior plan from April 1, 2024. Provides cash severance of 9-24 months base salary, incentive compensation, medical coverage, and equity treatment for executives upon involuntary termination or voluntary resignation for good reason.SEC filing →
- 2026-03-24Item 5.02MEDIUMChief Accounting Officer Mary Wilcox notified Solventum on March 20, 2026 of intent to retire and resign following search and appointment of her successor. No successor named. No reason cited beyond retirement intent.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Revenue shrinking — -3.0% YoY. Growth thesis broken unless recovery story develops.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $78.27 — A.R:R is negative (-1.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: MedSurg segment (57.9%). Chart setup: RSI 47 mid-range, Bollinger mid-band. Prior stop was $73.73. Score 4.8/10, moderate confidence.
Take-profit target: $81.75 (+4.4% upside). Prior stop was $73.73. Stop-loss: $73.73.
Concentration risk — Product: MedSurg segment (57.9%); Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.1): -0.5.
Solventum Corporation trades at a P/E of 9.6 (forward 11.1). TrendMatrix value score: 6.6/10. Verdict: Sell.
22 analysts cover SOLV with a consensus score of 3.7/5. Average price target: $82.
What does Solventum Corporation do?Solventum, spun off from 3M in April 2024, develops and commercializes healthcare solutions through MedSurg (57.9% of...
Solventum, spun off from 3M in April 2024, develops and commercializes healthcare solutions through MedSurg (57.9% of 2025 total sales), Dental Solutions (16.2%), and Health Information Systems (16.3%), with products sold in over 90 countries. Revenue comes from medical device, dental, and healthcare software sales to hospitals and clinics that bill Medicare, Medicaid, and private payers. The company carried approximately $5 billion in outstanding indebtedness as of December 31, 2025.